After a volatile stretch, yields in the Treasury bond market have stabilized. Concerns about the volatility in the bond and stock markets are leading investors to top-quality dividend stocks.
Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.
Baxter International's stock has been challenging to own for the past decade, initially due to high valuations and later due to execution concerns and an ugly acquisition. During the pandemic, health care stocks, including Baxter, underperformed expectations, with BAX peaking in April 2020 before declining. But the divestiture of the kidney care business will help the balance sheet, and management is optimistic toward 2025 performance.
Baxter International Inc. (NYSE:BAX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President and Chief Investor Relations Officer Brent Shafer - Chairman and Interim Chief Executive Officer Heather Knight - Chief Operating Officer Joel Grade - Executive Vice President and Chief Financial Officer Conference Call Participants Joanne Wuensch - Citi David Roman - Goldman Sachs Travis Steed - BofA Securities Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Larry Biegelsen - Wells Pito Chickering - Deutsche Bank Danielle Antalffy - UBS Operator Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material.
Baxter reports better-than-expected first-quarter results. However, the company's gross margin contracts.
While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Baxter's first-quarter results are likely to reflect the favorable impact of kidney care sales. Growth in infusion therapies, pharmaceuticals and patient support systems to continue.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2025 Annual Meeting) in a virtual format on Tuesday, May 6, 2025 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2025 Annual Meeting. Online access to the 2025 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2025 Annual Meeting in person. The virtual format provides a safe, c.
At the 2025 HIMSS Global Healthcare Conference, BAX unveils its Voalte Linq device, powered by Scotty assistant, a voice-activated technology.
LAS VEGAS--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today unveiled Voalte Linq device powered by Scotty assistant, the company's first voice-activated technology, at the 2025 HIMSS Global Healthcare Conference. Voalte Linq, a lightweight, wearable badge, is powered by Scotty assistant, a voice-activated technology, to better enable efficient, streamlined communication between care teams, with the goal of freeing up more of their time and energy to focus on.
Kontoor Brands Chair, President, and CEO Scott Baxter joins 'Mad Money' host Jim Cramer to talk acquiring Helly Hansen, international business, and more.